Shire Agrees to Talks in Inversion Deal After AbbVie Raises Bid to $53 Billion – New York Times


New York Times
Shire Agrees to Talks in Inversion Deal After AbbVie Raises Bid to $53 Billion
New York Times
In May, the American pharmaceutical giant Pfizer abandoned its bid to acquire AstraZeneca after the British drug maker rejected a $119 billion offer to merge, in part citing the execution risk over an inversion. Pfizer can make a renewed offer for
Pharmaceutical firm Shire to fall into hands of US rival AbbVie after it This is Money
Shire Pharmaceutical ready to accept AbbVie’s advancesProactive Investors UK
No Rival Bidder Emerging to Battle AbbVie for ShireWall Street Journal
USA TODAY -Quartz -Forbes
all 313 news articles >>

Source: pharmaceutical – Google News

Sharing information is key – Pharmaceutical Business News UK. Social Commerce and Social Media Management playing a big part. Suaju Ltd